Journal of Clinical Pediatrics >
Diagnosis and treatment of one case of refractory neuromyelitis optica spectrum disorder in adolescents
Received date: 2024-07-17
Accepted date: 2024-11-01
Online published: 2025-03-31
To preliminarily explore the feasibility and effectiveness of olfatomuzumab (OFA) in the treatment of patients with refractory neuromyelitis optica spectrum disorder (NMOSD). A 15-year-old adolescent female with seropositive AQP4-IgG and multiple relapses of refractory neuromyelitis optica spectrum disorder was given intravenous methylprednisolone, immunoglobulin, rituximab (RTX), and oral prednisone and mycophenolate mofetil for 5 years. She started to receive 4 doses of OFA (20 mg, subcutaneous injection) at intervals 9 months ago. The patient was observed for NMOSD recurrence, serum AQP4-IgG antibody titer, peripheral blood B cell level, and changes in cranial and spinal cord MRI during the 9-month period of OFA treatment. The patient's symptoms were stable without recurrence during the 9-month period of OFA treatment. The serum AQP4-IgG titer decreased, and the lesions in the cranial and spinal cord MRI decreased. There were no new lesions, and the tolerance was good without anaphylactic reactions or infectious adverse events. In addition to complete depletion of B cells, no lymphopenia or hypogammaglobulinemia was found. For patients with refractory NMOSD or other intolerant to immunotherapy, subcutaneous injection of OFA may be a safe and effective alternative treatment.
Key words： ofatumumab; AQP4-IgG; neuromyelitis optica spectrum disorders; refractory
ZHENG Nuo , CHEN Man , ZHANG Dongli , LIU Xiaoming . Diagnosis and treatment of one case of refractory neuromyelitis optica spectrum disorder in adolescents[J]. Journal of Clinical Pediatrics, 2025 , 43(4) : 301 -305 . DOI: 10.12372/jcp.2025.24e0688
| [1] | Wingerchuk DM, Lucchinetti CF. Neuromyelitis optica spectrum disorder[J]. N Engl J Med, 2022, 387(7): 631-639. |
| [2] | Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica[J]. Proc Natl Acad Sci U S A, 2011, 108(9): 3701-3706. |
| [3] | Huh SY, Kim SH, Hyun JW, et al. Mycopheno1ate mofetil in the treatment of neuromyelitis optica spectrum disorder[J]. JAMA Neuro1, 2014, 71(11): 1372-1378. |
| [4] | Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: asystematic review and meta-analysis[J]. JAMA Neurol, 2016, 73(11): 1342-1348. |
| [5] | Poupart J, Giovannelli J, Deschamps R, et al. Evaluation of efficacy and tolerability of first-line therapies in NMOSD[J]. Neurology, 2020, 94(15): E1645-E1656. |
| [6] | Bennett JL, O'Connor KC, Bar-Or A, et al. B lymphocytes in neuromyelitis optica[J]. Neurol Neuroimmunol Neuroinflamm, 2015, 2: e104. |
| [7] | Samjoo IA, Klotz L, Giovannoni G, et al. Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis[J]. Mult Scler Relat Disord, 2022, 66: 104031. |
| [8] | Basu B. Ofatumumab for rituximab-resistant nephrotic syndrome[J]. N Engl J Med, 2014, 370(13): 1268-1270. |
| [9] | Maillart E, Renaldo F, Papeix C, et al. Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder[J]. Neurol Neuroimmunol Neuroinflamm, 2020, 7(3): e683. |
| [10] | Chan KH, Lee CY. Treatment of neuromyelitis optica spectrum disorders[J]. Int J Mol Sci, 2021, 22(16): 8638. |
| [11] | Sellebjerg F, Blinkenberg M, Sorensen PS. Anti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis[J]. CNS Drugs, 2020, 34(3): 269-280. |
| [12] | Kim SH, Hyun JW, Kim HJ. Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder[J]. Neurochem Int, 2019, 130: 104347. |
| [13] | Focosi D, Tuccori M, Maggi F. Progressive multifocal leukoencepha lopathy and anti-CD20 monoclonal antibodies: what do we know after 20 years of rituximab[J]. Rev Med Virol, 2019, 29(6): e2077. |
| [14] | Herter S, Herting F, Muth G, et al. GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity[J]. Haematologica, 2018, 103(2): e78-e81. |
| [15] | Mirmosayyeb O, Shaygannejad V, Barzegar M, et al. Efficacy and safety of rituximab in treating patients with neuromyelitis optica spectrum disorder (NMOSD): a systematic review and meta-analysis[J]. Autoimmun Rev, 2021, 20(2): 102727. |
| [16] | Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas[J]. Blood, 2004, 104(6): 1793-1800. |
| [17] | Klein C, Lammens A, Schafer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties[J]. Mabs, 2013, 5(1): 22-33. |
| [18] | Hauser SL, Cross AH, Winthrop K, et al. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years[J]. Mult Scler, 2022, 28(10): 1576-1590. |
| [19] | Cohen M, Romero G, Bas J, et al. Monitoring CD27+ memory b-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: results from a bicentric study[J]. J Neurol Sci, 2017, 373: 335-338. |
| [20] | Cao S, Wang X, Ji X, et al. B-cell proliferation characteristics and monitoring significance under the modified reduced-dose rituximab regimen for NMOSD: a real-world case series study[J]. Mult Scler Relat Disord, 2023, 70: 104524. |
| [21] | Lebrun C, Cohen M, Rosenthal-Allieri MA, et al. Only follow-up of memory B cells helps monitor rituximab administration to patients with neuromyelitis optica spectrum disorders[J]. Neurol Ther, 2018, 7(2): 373-383. |
| [22] | 中国免疫学会神经免疫分会. 中国视神经脊髓炎谱系疾病诊断与治疗指南(2021版)[J]. 中国神经免疫学和神经病学杂志, 2021, 28(6): 423-436. |
| Neuroimmunology Branch, Chinese Society of Immunology. Guidelines for the diagnosis and treatment of neuromyelitis optica spectrum disorders in China (2021 edition)[J]. Zhongguo Shenjingmianyixue He Shenjingbingxue Zazhi, 2021, 28(6): 423-436. | |
| [23] | 中华医学会眼科学分会神经眼科学组. 中国脱髓鞘性视神经炎诊断和治疗循证指南(2021年)[J]. 中华眼科杂志, 2021, 57(3): 171-186. |
| Neuro-ophthalmology Group of Ophthalmology Branch of Chiese Medical Association. Evidence-base guidelines for diagnosis and treatment of demyelinating optic neuritis in China(2021)[J]. Zhonghua Yanke Zazhi, 2021, 57(3): 171-186. | |
| [24] | Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome)[J]. Neurology, 1999, 53(5): 1107-1114. |
| [25] | Papp V, Magyari M, Aktas O, et al. Worldwide incidence and prevalence of neuromyelitis optica. A systematic review[J]. Neurology, 2021, 96(2): 59-77. |
/
| 〈 |
|
〉 |
